[1]王敏 李惠平＊ 赵红梅① 雷玉涛① 王丽娜 王晶 刘雅昕.Bcl2、cyclin A2和PI3K在激素受体阴性乳腺癌中的表达及意义[J].中国微创外科杂志,2013,13(8):713-716.
　Wang Min*,Li Huiping*,Zhao Hongmei,et al.The Expression of Bcl2, Cyclin A2 and PI3K in Hormone Receptor Negative Breast Cancer and Their Significance[J].Chinese Journal of Minimally Invasive Surgery,2013,13(8):713-716.
点击复制

Bcl2、cyclin A2和PI3K在激素受体阴性乳腺癌中的表达及意义()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
13
期数:
2013年8期
页码:
713-716
栏目:
论著
出版日期:
2013-08-20

文章信息/Info

Title:
The Expression of Bcl2, Cyclin A2 and PI3K in Hormone Receptor Negative Breast Cancer and Their Significance
作者:
王敏 李惠平＊ 赵红梅① 雷玉涛① 王丽娜 王晶 刘雅昕
北京大学肿瘤医院暨北京市肿瘤防治研究所乳腺内科恶性肿瘤发病机制及转化研究教育部重点实验室，北京100142
Author(s):
Wang Min*;  Li Huiping*;  Zhao Hongmei;  et al.
*Department of Breast Oncology, Peking University Caner Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing 100142, China
关键词:
激素受体阴性乳腺癌; B淋巴细胞瘤/白血病2基因; 细胞周期素A2; 磷酸肌醇3激酶; 实时聚合酶链反应
Keywords:
Hormone receptor negative breast cancer;  Bcl2; Cyclin A2; PI3K; Real time PCR
分类号:
R737.9
文献标志码:
A
摘要:
目的探讨激素受体阴性乳腺癌中B淋巴细胞瘤/白血病2基因(Bcell lymphoma/leukemia2，Bcl2)、细胞周期素A2(cyclin A2)和磷酸肌醇3激酶（phosphoinositide 3kinase，PI3K）的表达及意义。方法采用实时聚合酶链反应（real time polymerase chain reaction，RTPCR）方法检测Bcl2、cyclin A2和PI3K在激素受体阴性乳腺癌组织（58例）、乳腺正常组织（14例）中的表达水平，并采用MannWhitney U检验分析其与临床病理特征的关系。结果与乳腺正常组织相比，激素受体阴性乳腺癌中Bcl2表达降低，而cyclin A2和PI3K表达增高（P＜0.05）。在乳腺癌组织中，Bcl2在TNM分期Ⅲ期、组织学分级Ⅲ级和出现转移复发的患者中表达水平降低（P＜0.05），但其表达在不同年龄、肿瘤大小和淋巴结转移的组间差异无显著性（P＞0.05）；cyclin A2在转移复发的患者中显著高表达（P＜0.05），但在不同的年龄、肿瘤大小、组织学分级、TNM分期和淋巴结状态的组间差异均无显著性（P＞0.05）；PI3K在有淋巴结转移和TNM分期Ⅲ期的患者中高表达（P＜005），但其表达在不同年龄、肿瘤大小、组织学分级以及是否转移复发的组间差异均无显著性（P＞0.05）。结论Bcl2低表达、cyclin A2和PI3K高表达可能与激素受体阴性乳腺癌的发生发展有关。
Abstract:
ObjectiveTo study the expression of Bcl2, cyclin A2 and PI3K in hormone receptor negative breast cancer and their clinical significance.MethodsBcl2, cyclin A2 and PI3K amplifications were analyzed using real time PCR in hormone receptor negative breast cancer (58 cases) and normal breast tissues (14 cases). Their relationship with clinicopathological characteristics were analyzed using MannWhitney U test.ResultsCompared with normal breast tissue, the expression of Bcl2 decreased in hormone receptor negative breast cancer, while the expression of cyclin A2 and PI3K increased (P＜0.05). Bcl2 expression in patients with stage Ⅲ, grade Ⅲ or tumor metastasis group were significantly lower（P＜0.05）. But there was no association with age, tumor size and lymph node status（P＞0.05）. The high expression of cyclin A2 was observed in patients with metastasis or recurrence（P＜0.05）. The expression of cyclin A2 was not significantly different in different groups in terms of age, tumor size, grade, lymph node status and stage（P＞0.05）. PI3K expression was significantly higher in the patients with lymph node metastasis or stage Ⅲ（P＜0.05）. But there was no association with age, tumor size, grade or metastasis （P＞0.05）.ConclusionBcl2 low expression, cyclin A2 and PI3K high expression might be closely correlated with the occurrence and development of hormone receptor negative breast cancer.

参考文献/References:

[1]Zaha DC,Lazr E.Molecular characterization of apoptosis by the immunohistochemical evaluation of Bcl2 in breast cancer.Rom J Morphol Embryol,2012,53(1):155-160.
[2]MartínezArribas F,Alvarez T,Del Val G,et al.Bcl2 expression in breast cancer:a comparative study at the mRNA and protein level.Anticancer Res,2007,27(1A):219-222.
[3]Yao Q,Chen J,Lv Y,et al.The significance of expression of autophagyrelated gene Beclin,Bcl2,and Bax in breast cancer tissues.Tumour Biol,2011,32(6):1163-1171.
[4]Linjawi A,Kontogiannea M,Halwani F,et al.Prognostic significance of p53,bcl2,and Bax expression in early cancer.J Am Coll Surg,2004,198(1):83-90.
[5]Schymik B,Buerger H,Krmer A,et al.Is there’progression through grade’in ductal invasive breast cancer?Breast Cancer Res Treat,2012,135(3):693-703.
[6]Dawson SJ,Makretsov N,Blows FM,et al.BCL2 in breast cancer:a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.Br J Cancer,2010,103(5):668-675.
[7]Knowlton K,Mancini M,Creason S,et al.Bcl2 slows in vitro breast cancer growth despite its antiapoptotic effect.J Surg Res,1998,76(1):22-26.
[8]Poikonen P,Sjstrm J,Amini RM,et al.CyclinA as a marker for prognosis and chemotherapy response in advanced breast cancer.Br J Cancer,2005,93(5):515-519.
[9]肖宇,李惠平,雷玉涛,等.乳腺癌新辅助化疗疗效及ER/PR,HER2,Ki67,CyclinA2的化疗预测作用.中国微创外科杂志,2011,11(2):163-167.
[10]Li HP,Ji JF,Hou KY,et al.Prediction of recurrence risk in early breast cancer using human epidermal growth factor 2 and cyclinA2.Chin Med J(Engl),2010,123(4):431-437.
[11]Dai L,Liu Y,Liu J,et al.A novel CyclinE/CyclinACDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival :Implications in cancer therapy.Cancer Lett,2013,333(1):103-112.
[12]Nilsson C,Koliadi A,Johansson I,et al.High proliferation is associated with inferior outcome in male breast cancer patients.Mod Pathol,2013,26(1):87-94.
[13]Ahlin C,Zhou W,Holmqvist M,et al.CyclinA is a proliferative marker with good prognostic value in nodenegative breast cancer.Cancer Epidemiol Biomarkers Prev,2009,18(9):2501-2506.
[14]Utermark T,Rao T,Cheng H,et al.The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.Genes Dev,2012,26(14):1573-1586.
[15]张晓霞,费军伟,于晓伟,等.卵巢癌组织中PI3K的表达及意义.吉林大学学报(医学版),2008,34(6):1027-1030.
[16]Creighton CJ,Fu X,Hennessy BT,et al.Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogenreceptor (ER) levels and activity in ER+ breast cancer.Breast Cancer Res,2010,12(3):R40.
[17]Rabi T,Huwiler A,ZangemeisterWittke U.AMRMe inhibits PI3K/Akt signaling in hormonedependent MCF7 breast cancer cells and inactivates NFκB in hormoneindependent MDAMB231 cells.Mol Carcinog,2013.［Epub ahead of print］
[18]Lin KL,Chien CM,Hsieh CY,et al.Antimetastatic potential of cardiotoxin III involves inactivation of PI3K/Akt and p38 MAPK signaling pathways in human breast cancer MDAMB231 cells.Life Sci,2012,90(1-2):54-65.
[19]Jensen JD,Knoop A,Laenkholm AV,et al. PIK3CA mutations,PTEN,and pHER2 expression and impact on outcome in HER2positive earlystage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.Ann Oncol,2012,23(8):2034-2042.
[20]LópezKnowles E,O'Toole SA,McNeil CM,et al.PI3K pathway activation in breast cancer is associated with the basallike phenotype and cancerspecific mortality.Int J Cancer,2010,126(5):1121-1131.
[21]Kim R,Kaneko M,Arihiro K,et al.Extranuclear expression of hormone receptors in primary breast cancer.Ann Oncol,2006,17(8):1213-1220.
[22]Yamaguchi H,Yoshida S,Muroi E,et al.Phosphoinositide 3kinase signaling patyway mediated by p110α regulates invadopodia formation.J Cell Biol,2011,193(7):1275-1288.

备注/Memo

备注/Memo:
＊通讯作者，Email：huipingli2012@hotmail.com ①（北京大学第三医院普外科，北京100191）
更新日期/Last Update: 2014-10-14